Basilea Snags Extended $226M+ Antifungal Deal With Pfizer By Sam | November 30, 2017 Basilea eligible to receive additional upfront and milestone payments of up to USD 226 million and mid-teen royalties on sales. Source: BioSpace Posted in BioPharma